Drug Trial Radar · NCT03911505
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Actual
Start
Feb 13, 2020
Primary completion
Mar 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Conditions
- Pompe Disease (Late-onset)
Interventions
Cipaglucosidase AlfaBiological
Enzyme Replacement Therapy via intravenous infusion
MiglustatDrug
Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) from baselineTime frame: 52 weeks
Locations
17 sites in 6 countries. Site status is shown where the registry gives one.
University of Florida Clinical Research Center
Gainesville, Florida
Wolfson Children's Hospital
Jacksonville, Florida
Woodruff Memorial Research Building
Atlanta, Georgia
St. Louis Children's Hospital
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
University of Utah, Clinical and Translational Sciences Institute
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
University of Calgary
Calgary, Alberta, Canada
SphinCS GmbH Clinical Science for LSD
Hochheim am Main, Hesse, Germany
San Gerardo Hospital
Monza, Italy
Gunma University Hospital
Gunma, Japan
Tohoku University Hospital
Miyagi, Japan
Tokyo Women's Medical University
Tokyo, Japan
Izumi City General Hospital
Osaka, Izumi-Shi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.